Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.

Blood advances·2026
Same author

When will circulating tumor DNA be ready for prime time in lymphoma?

Clinical advances in hematology & oncology : H&O·2026
Same author

Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma-Where we are and where we're headed.

Seminars in hematology·2026
Same author

A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.

Blood advances·2026
Same author

SOHO State of the Art Updates and Next Questions | Addressing the Transformative Questions in Aggressive B-Cell Lymphomas.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Axes of biological variation in diffuse large B cell lymphoma.

Cancer cell·2026

Related Experiment Video

Updated: May 17, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Diffuse large B cell lymphoma: molecular targeted therapy.

Mark Roschewski1, Kieron Dunleavy, Wyndham H Wilson

  • 1Lymphoma Therapeutics Section, Metabolism Branch, National Cancer Institute, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA. roschewskimj@mail.nih.gov

International Journal of Hematology
|October 23, 2012
PubMed
Summary

Diffuse large B cell lymphoma (DLBCL) is a common cancer that often relapses. New targeted therapies are emerging, shifting treatment away from chemotherapy for better outcomes in high-risk patients.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: May 17, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma in the USA.
  • While curable, up to 40% of DLBCL patients experience relapse or treatment failure.
  • The disease's biological heterogeneity presents challenges for effective treatment.

Purpose of the Study:

  • To highlight the shift in DLBCL treatment paradigms.
  • To emphasize the role of targeted therapies in managing DLBCL.
  • To underscore the importance of clinical trials for advancing DLBCL treatment.

Main Methods:

  • Review of current understanding of DLBCL biology.
  • Analysis of emerging targeted therapy approaches.
  • Emphasis on the role of clinical trial participation.

Main Results:

  • DLBCL exhibits significant biological complexity with diverse oncogenic drivers.
  • Targeted therapies show promise by inhibiting essential growth and survival pathways.
  • A paradigm shift towards targeted agents is underway, moving from conventional chemotherapy.

Conclusions:

  • Understanding DLBCL's molecular complexity enables targeted treatment strategies.
  • Targeted agents offer a new frontier for improving outcomes in relapsed or refractory DLBCL.
  • Clinical trials are crucial for validating and implementing these novel therapies to improve patient survival.